DK1140175T3 - Antistoffer mod trunkeret VEGF-D og anvendelser deraf - Google Patents

Antistoffer mod trunkeret VEGF-D og anvendelser deraf

Info

Publication number
DK1140175T3
DK1140175T3 DK99969995T DK99969995T DK1140175T3 DK 1140175 T3 DK1140175 T3 DK 1140175T3 DK 99969995 T DK99969995 T DK 99969995T DK 99969995 T DK99969995 T DK 99969995T DK 1140175 T3 DK1140175 T3 DK 1140175T3
Authority
DK
Denmark
Prior art keywords
vegf
antibodies against
antibodies
vegfr
interfere
Prior art date
Application number
DK99969995T
Other languages
English (en)
Inventor
Marc G Achen
Steven Alan Stacker
Original Assignee
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst Cancer Res filed Critical Ludwig Inst Cancer Res
Application granted granted Critical
Publication of DK1140175T3 publication Critical patent/DK1140175T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y10S530/809—Fused cells, e.g. hybridoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK99969995T 1998-12-21 1999-12-21 Antistoffer mod trunkeret VEGF-D og anvendelser deraf DK1140175T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11325498P 1998-12-21 1998-12-21
US13455699P 1999-05-17 1999-05-17

Publications (1)

Publication Number Publication Date
DK1140175T3 true DK1140175T3 (da) 2006-08-14

Family

ID=26810852

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99969995T DK1140175T3 (da) 1998-12-21 1999-12-21 Antistoffer mod trunkeret VEGF-D og anvendelser deraf

Country Status (13)

Country Link
US (3) US6383484B1 (da)
EP (1) EP1140175B1 (da)
JP (1) JP4632543B2 (da)
KR (1) KR20010081089A (da)
CN (1) CN1330555A (da)
AT (1) ATE322909T1 (da)
AU (2) AU770332B2 (da)
CA (1) CA2355896A1 (da)
DE (1) DE69930872T8 (da)
DK (1) DK1140175T3 (da)
ES (1) ES2259247T3 (da)
PT (1) PT1140175E (da)
WO (1) WO2000037025A2 (da)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6824777B1 (en) 1992-10-09 2004-11-30 Licentia Ltd. Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
EP1353952B1 (en) 1994-11-14 2007-04-11 Ludwig Institute For Cancer Research Flt4(vegfr-3) as a target for tumor imaging and anti-tumor therapy
DE69634412T3 (de) * 1995-09-29 2013-07-04 Vegenics Pty Ltd Regulierte gene und ihre verwendungen
WO1998007832A1 (en) 1996-08-23 1998-02-26 Ludwig Institute For Cancer Research Recombinant vascular endothelial cell growth factor d (vegf-d)
US7125714B2 (en) 1997-02-05 2006-10-24 Licentia Ltd. Progenitor cell materials and methods
US20020137890A1 (en) * 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2000058511A1 (en) * 1999-03-26 2000-10-05 Ludwig Institute For Cancer Research Screening and therapy for lymphatic disorders involving the flt4 receptor tyrosine kinase (vegfr-3)
EP1248642A4 (en) * 2000-01-18 2005-05-18 Ludwig Inst Cancer Res PEPTIDOMIMETIC INHIBITOR OF VEGF-D / VEGF-C / VEGF
AU3988401A (en) * 2000-02-25 2001-09-03 Ludwig Inst Cancer Res Materials and methods involving hybrid vascular endothelial growth factor dnas and proteins
PT1259248E (pt) * 2000-03-02 2005-04-29 Ludwig Inst Cancer Res Metodos para tratar, rastrear e detectar cancros que expressam o factor de crescimento vascular endotelial d
US20020102260A1 (en) 2000-03-02 2002-08-01 Marc Achen Methods for treating neoplastic disease characterized by vascular endothelial growth factor D expression, for screening for neoplastic disease or metastatic risk, and for maintaining vascularization of tissue
EP1299419A2 (en) * 2000-05-24 2003-04-09 Imclone Systems, Inc. Bispecific immunoglobulin-like antigen binding proteins and method of production
US7611711B2 (en) * 2001-01-17 2009-11-03 Vegenics Limited VEGFR-3 inhibitor materials and methods
US20020164624A1 (en) * 2001-02-12 2002-11-07 Waldemar Debinski VEGF-D expression in brain cancer
US20050232921A1 (en) * 2001-04-13 2005-10-20 Rosen Craig A Vascular endothelial growth factor 2
CA2444632A1 (en) 2001-04-13 2002-10-24 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
NZ530212A (en) 2001-06-13 2006-09-29 Genmab As An isolated human monoclonal antibody that binds to human epidermal growth factor receptor (EGFR)
CA2452058A1 (en) * 2001-06-26 2003-01-09 Imclone Systems Incorporated Bispecific antibodies that bind to vegf receptors
WO2003006104A2 (en) * 2001-07-12 2003-01-23 Ludwig Institute For Cancer Research Lymphatic endothelial cells materials and methods
US20030113324A1 (en) * 2001-10-01 2003-06-19 Kari Alitalo Neuropilin/VEGF-C/VEGFR-3 materials and methods
US20040214766A1 (en) * 2001-10-01 2004-10-28 Kari Alitalo VEGF-C or VEGF-D materials and methods for treatment of neuropathologies
WO2004009773A2 (en) * 2002-07-23 2004-01-29 Ludwig Institute For Cancer Research Methods and compositions for activating or inhibiting vegf-d and vegf-c
US7608684B2 (en) * 2002-11-12 2009-10-27 Mochida Pharmaceuticals Co., Ltd. Soluble CD14 antigen
ES2340266T3 (es) 2002-11-12 2010-06-01 Mochida Pharmaceutical Co., Ltd. Kit de analisis para cd14 humana de bajo peso molecular y anticuerpo.
DE10256410B3 (de) * 2002-12-02 2004-03-11 Daimlerchrysler Ag Verfahren zum Energiemanagement von Klimaanlagen
US20040120950A1 (en) * 2002-12-20 2004-06-24 Kari Alitalo Modulation of VEGF-C/VEGFR-3 interactions in the treatment of rheumatoid arthritis
US20040248796A1 (en) * 2003-02-04 2004-12-09 Kari Alitalo VEGF-B and PDGF modulation of stem cells
EP1635860A2 (en) * 2003-06-12 2006-03-22 Ludwig Institute For Cancer Research Use of vegf-c or vegf-d in reconstructive surgery
WO2005016963A2 (en) * 2003-06-12 2005-02-24 Ludwig Institute For Cancer Research Heparin binding veger-3 ligands
NZ592039A (en) 2003-08-27 2013-03-28 Ophthotech Corp Combination therapy for the treatment of ocular neovascular disorders
US20050282233A1 (en) * 2004-03-05 2005-12-22 Ludwig Institute For Cancer Research Multivalent antibody materials and methods for VEGF/PDGF family of growth factors
WO2005087177A2 (en) * 2004-03-05 2005-09-22 Ludwig Institute For Cancer Research Chimeric anti-vegf-d antibodies and humanized anti-vegf-d antibodies and methods of using same
US7595149B1 (en) 2004-11-08 2009-09-29 University Of Kentucky Research Foundation Methods for cancer detection
TWI428143B (zh) 2006-01-18 2014-03-01 Gen Hospital Corp 增加淋巴功能之方法
US7667880B2 (en) * 2006-02-10 2010-02-23 Adobe Systems, Incorporated Method and apparatus for previewing digital motion picture content
US9073997B2 (en) 2007-02-02 2015-07-07 Vegenics Pty Limited Growth factor antagonists for organ transplant alloimmunity and arteriosclerosis
AR066660A1 (es) * 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
DE102007038730A1 (de) * 2007-08-16 2009-02-19 Carl Zeiss Meditec Ag Nachweis des menschlichen Vascular Endothelial Growth Factor
CN101245106B (zh) * 2007-12-04 2011-07-20 澳赛尔斯生物技术（上海）有限公司 抗vegf受体单克隆抗体及其制备方法和应用
US7811776B2 (en) 2007-12-05 2010-10-12 University Of Cincinnati Use of VEGF-D in the diagnosis of lymphangioleiomyomatosis (LAM) disease
US20110142839A1 (en) * 2008-05-30 2011-06-16 Vegenics Limited Treatment of pulmonary edema
JP2011526892A (ja) 2008-06-30 2011-10-20 アンジオブラスト システムズ，インコーポレーテッド 併用療法を使用した眼疾患及び過剰血管新生の治療
US11298113B2 (en) 2008-10-01 2022-04-12 Covidien Lp Device for needle biopsy with integrated needle protection
US9782565B2 (en) 2008-10-01 2017-10-10 Covidien Lp Endoscopic ultrasound-guided biliary access system
US9332973B2 (en) 2008-10-01 2016-05-10 Covidien Lp Needle biopsy device with exchangeable needle and integrated needle protection
US9186128B2 (en) 2008-10-01 2015-11-17 Covidien Lp Needle biopsy device
US8968210B2 (en) 2008-10-01 2015-03-03 Covidien LLP Device for needle biopsy with integrated needle protection
CA2751445C (en) * 2009-02-06 2018-06-19 Pepscan Systems B.V. Truncated cystine-knot proteins
EP3912643B8 (en) 2009-02-13 2023-08-23 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
JP2012522491A (ja) * 2009-04-03 2012-09-27 ベジニクス ピーティーワイ リミテッド 抗ｖｅｇｆ−ｄ抗体
EP3009455A1 (en) 2009-09-16 2016-04-20 Immunomedics Inc. Class i anti-cea antibodies and uses thereof
ES2978177T3 (es) 2009-12-02 2024-09-06 Immunomedics Inc Combinación de radio inmunoterapia y conjugados anticuerpo-fármaco para mejorar la terapia contra el cáncer
EP2538965B1 (en) 2010-02-25 2017-04-12 Schepens Eye Research Institute Therapeutic compositions for the treatment of dry eye disease
AU2012250924B2 (en) 2011-05-02 2017-05-25 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
AU2013302696B9 (en) 2012-08-14 2018-08-09 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
SI2900277T1 (sl) 2012-12-13 2022-05-31 Immunomedics, Inc. Odmerki imunokonjugatov protiteles in SN-38 za boljšo učinkovitost in zmanjšano toksičnost
PT2956476T (pt) 2013-02-18 2020-02-21 Vegenics Pty Ltd Moléculas de ligação e usos destas
AU2014286996A1 (en) 2013-07-12 2016-01-07 Iveric Bio, Inc. Methods for treating or preventing ophthalmological conditions
WO2015126548A1 (en) 2014-02-21 2015-08-27 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to trop-2 expressing cells
US9139649B2 (en) 2014-02-25 2015-09-22 Immunomedics, Inc. Humanized anti-CD22 antibody
WO2015200260A1 (en) 2014-06-24 2015-12-30 Immunomedics, Inc. Anti-histone therapy for vascular necrosis in severe glomerulonephritis
CN117138060A (zh) 2014-10-07 2023-12-01 免疫医疗公司 抗体-药物缀合物的新辅助剂用途
WO2016172427A1 (en) 2015-04-22 2016-10-27 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
EP4257134A3 (en) 2015-06-25 2024-01-24 Immunomedics, Inc. Combining anti-hla-dr or anti-trop-2 antibodies with microtubule inhibitors, parp inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
PL3316885T3 (pl) 2015-07-01 2021-12-06 Immunomedics, Inc. Immunokoniugaty przeciwciało-sn-38 z linkerem cl2a
CA3012718A1 (en) 2016-02-08 2017-08-17 Vitrisa Therapeutics, Inc. Compositions with improved intravitreal half-life and uses thereof
CN108794629A (zh) * 2018-06-28 2018-11-13 浙江众意生物科技有限公司 一种vegf-d单克隆抗体及试剂盒
US20250073349A1 (en) 2021-05-10 2025-03-06 Kawasaki Institute Of Industrial Promotion Antibody having reduced binding affinity for antigen

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998033917A1 (en) * 1994-11-14 1998-08-06 The Ludwig Institute For Cancer Research Vascular endothelial growth factor c (vegf-c) protein and gene, mutants thereof, and uses thereof
WO1998002543A1 (fr) * 1996-07-15 1998-01-22 Chugai Research Institute For Molecular Medicine, Inc. Nouveaux facteurs analogues au vegf
WO1998007832A1 (en) * 1996-08-23 1998-02-26 Ludwig Institute For Cancer Research Recombinant vascular endothelial cell growth factor d (vegf-d)
AU5439998A (en) * 1996-12-06 1998-06-29 Zymogenetics Inc. Vascular endothelial growth factor
CN1345247A (zh) * 1997-12-24 2002-04-17 路德维格癌症研究所 表达血管内皮生长因子d的表达载体和细胞系以及治疗黑素瘤的方法
EP1179541B1 (en) * 1999-04-28 2004-06-16 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting VEGF

Also Published As

Publication number Publication date
DE69930872T2 (de) 2006-11-30
EP1140175A2 (en) 2001-10-10
PT1140175E (pt) 2006-06-30
US7097986B2 (en) 2006-08-29
AU3343200A (en) 2000-07-12
ATE322909T1 (de) 2006-04-15
DE69930872D1 (de) 2006-05-24
KR20010081089A (ko) 2001-08-25
DE69930872T8 (de) 2007-05-03
EP1140175A4 (en) 2003-03-05
WO2000037025A3 (en) 2000-11-16
AU2004202080A1 (en) 2004-06-10
JP4632543B2 (ja) 2011-02-16
US6383484B1 (en) 2002-05-07
JP2002532113A (ja) 2002-10-02
WO2000037025A2 (en) 2000-06-29
AU770332B2 (en) 2004-02-19
CA2355896A1 (en) 2000-06-29
CN1330555A (zh) 2002-01-09
EP1140175B1 (en) 2006-04-12
US20040141917A1 (en) 2004-07-22
ES2259247T3 (es) 2006-09-16
US6730489B1 (en) 2004-05-04

Similar Documents

Publication Publication Date Title
DK1140175T3 (da) Antistoffer mod trunkeret VEGF-D og anvendelser deraf
ATE172743T1 (de) Nachweis von kollagenabbau -i(in vivo)
DE69841273D1 (de) Verfahren zur identifikation von bindestellendomänen, die ihre epitopbindefähigkeit beibehalten
ATE517922T1 (de) Stabilisierte einzel-domänen-antikörper in einer pharmazeutischen zusammensetzung ausgestaltet für inhalation
DK0724456T3 (da) CD40-Antistoffer
IL101728A0 (en) Human notch and delta,binding domains in toporhythmic proteins,and methods based thereon
ATE178907T1 (de) Rezeptorbindende region des diphtherietoxius
NZ236511A (en) Polypeptides containing sequences from residues 61 to 82 or 104 to 129 of human il-4 or subsequences thereof; antibodies and pharmaceutical compositions
NO20000934L (no) Adipocyttspesifikke proteinhomologer
BR8606615A (pt) Polipeptideos complementares a peptideos ou proteinas tendo uma sequencia de aminoacidos ou sequencia de codificacao de nucleotidios conhecida ao menos parcialmente e metodos de projeto dos mesmos
DE69232309D1 (de) Weitgehend reine rezeptorartige, tgf-beta-1-bindende moleküle und deren verwendungen
NO986088L (no) Polypeptider med evnen til Õ danne antigenbindende strukturer med spesifisitet for Rhesus D-antigener, DNA som koder for disse, fremgangsmÕter for fremstilling av disse og anvendelse av disse
DE69834828D1 (de) Verfahren zur konstruktion von agonisten und antagonisten des igf-rezeptors (1-462)
DE69834643D1 (de) Adipozyten-spezifische protein homologe
EE05497B1 (et) Polüpeptiid, lahustuv CRAM-1 polüpeptiid, polünukleotiid ja antikeha
CY1108568T1 (el) Αναστολεας για διαγνωση και θεραπεια ασθενων με αιμορροφιλια α
ATE132162T1 (de) Humane gammainterferonantagonisten
ATE410514T1 (de) Calciumbindende rekombinante antikörper gegen protein c
ATE180489T1 (de) Für leberzellkarzinom spezifisches onkogen
DE59508137D1 (de) Spezifische bindungssubstanzen für antikörper und deren verwendung für immunoassays oder vakzine
NO970113L (no) Kollagenbindende protein eller polypeptid
AR018045A1 (es) Proteina placentaria 13 y polipetido, molecula de adn que los codifica, anticuerpos capaces de enlazarse a ellos, metodo para la deteccion decomplicaciones relacionadas con el embarazo, metodo recombinante para la produccion de dicha proteina y un equipo para el diagnostico de complicacionesrelacion
NO984522D0 (no) Monoklonale antistoffer som binder humant veksthormon (hGH)
ATE342972T1 (de) Ifn rezeptor 1 bindende proteine, dafür kodierende dna und verfahren zur regulierung der zellulären antwort auf interferone
MY142458A (en) Peptides that inhibit the propagation of newcastle disease virus